McKenzie Research
Steven McKenzie

Contact

Name: Steven McKenzie, MD, PhD
Positions:
  • Director, Cardeza Foundation for Hematologic Research
  • Director, Division of Hematology
  • Director, Hereditary Anemias Program
  • Associate Director, Hemophilia Center
  • Professor of Medicine
Organization: Department of Medicine, Division of Hematology
Contact Number(s):

Recent Publications

The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology

PCTP contributes to human platelet activation by enhancing dense granule secretion

Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis

Platelets release mitochondrial antigens in systemic lupus erythematosus

Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing

FcgRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus

Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock

Clinical Transformation in Care for Patients With Sickle Cell Disease at an Urban Academic Medical Center

GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets

Platelets disseminate extracellular vesicles in lymph in rheumatoid arthritis

Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia

The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition

Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies

Erratum: TULA-2 protein phosphatase suppresses activation of Syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346, a regulatory site of Syk (The Journal of Biological Chemistry (2016) 291 (22427-22441) DOI: 10.1074/jbc.M116.743732)

Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia

TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcγRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice

TULA-2 protein phosphatase suppresses activation of syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346 a regulatory site of syk

Mice expressing low levels of CalDAG-GEFI exhibit markedly impaired platelet activation with minor impact on hemostasis

Identification of novel Syk-independent functional roles of FcγRIIa in platelet outside-in signaling using transgenic mice expressing human FcγRIIa

Syk inhibition in ischemic stroke

Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia

The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21)